Barclays
BTAI icon

Barclays’s BioXcel Therapeutics BTAI Stock Holding History

Barclays’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-8
Closed -$14 – 5504
2025
Q2 		$14 Sell
8
-1,902
-100% -$3.15K ﹤0.01% 5147
2025
Q1 		$3.88K Buy
1,910
+1,904
+31,733% +$7.11K ﹤0.01% 4954
2024
Q4 		$33 Hold
6
– – ﹤0.01% 5209
2024
Q3 		$54 Sell
6
-3
-33% -$40 ﹤0.01% 5203
2024
Q2 		$176 Sell
9
-914
-99% -$30.6K ﹤0.01% 4736
2024
Q1 		$41.7K Sell
923
-820
-47% -$39.1K ﹤0.01% 4651
2023
Q4 		$82.3K Buy
1,743
+1,264
+264% +$70.3K ﹤0.01% 4680
2023
Q3 		$19.4K Sell
479
-5,816
-92% -$588K ﹤0.01% 4186
2023
Q2 		$671K Buy
6,295
+2,794
+80% +$930K ﹤0.01% 2568
2023
Q1 		$1.05M Buy
3,501
+3,180
+991% +$1.36M ﹤0.01% 2701
2022
Q4 		$110K Buy
321
+270
+529% +$65.3K ﹤0.01% 4170
2022
Q3 		$10K Sell
51
-101
-66% -$23.4K ﹤0.01% 4292
2022
Q2 		$32K Sell
152
-29
-16% -$6.1K ﹤0.01% 4216
2022
Q1 		$61K Sell
181
-1,127
-86% -$327K ﹤0.01% 4030
2021
Q4 		$426K Buy
1,308
+662
+102% +$284K ﹤0.01% 3273
2021
Q3 		$314K Buy
646
+276
+75% +$121K ﹤0.01% 3404
2021
Q2 		$172K Buy
+370
New +$202K ﹤0.01% 3622
2021
Q1 		– Sell
-30
Closed -$22K – 4712
2020
Q4 		$22K Sell
30
-1,750
-98% -$1.36M ﹤0.01% 4654
2020
Q3 		$1.24M Buy
1,780
+1,742
+4,584% +$1.31M ﹤0.01% 2505
2020
Q2 		$32K Buy
+38
New +$24.8K ﹤0.01% 5086
2020
Q1 		– Sell
-434
Closed -$101K – 6150
2019
Q4 		$101K Buy
434
+248
+133% +$24.9K ﹤0.01% 5473
2019
Q3 		$21K Sell
186
-57
-23% -$8.99K ﹤0.01% 6197
2019
Q2 		$43K Buy
+243
New +$41.2K ﹤0.01% 6164
2018
Q2 		– Sell
-38,641
Closed -$6.33M – 6980
2018
Q1 		$6.33M Buy
+38,641
New +$6.45M ﹤0.01% 1475

Other funds holding BTAI

Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
OFA
Oaktree Fund Advisors Los Angles, California $56.9M AUM 80.32% 1-Year Est. Return

Barclays's BTAI Position: Q3 2025 in Review

Barclays sold out of BioXcel Therapeutics (BTAI) in Q3 2025, closing a stake of 8 shares — an estimated $14 sold.

Barclays first reported a position in BTAI in Q1 2018 and held it in 24 quarters. The position peaked at $6.33M in Q1 2018. 35 funds tracked by Wall St. Rank hold BTAI as of Q3 2025.

  • Barclays reported no remaining BioXcel Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Barclays sold 8 BioXcel Therapeutics shares in Q3 2025, an estimated $14.
  • Barclays first reported a position in BioXcel Therapeutics in Q1 2018 and held it in 24 quarters.
  • Barclays's BioXcel Therapeutics position peaked at $6.33M in Q1 2018.
  • 35 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q3 2025.

Based on Barclays's 13F filing for Q3 2025, filed 12 Nov 2025.